These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23196542)

  • 1. [Challenge toward gene-therapy using iPS cells for Duchenne muscular dystrophy].
    Oshimura M; Kazuki Y; Uno N
    Rinsho Shinkeigaku; 2012; 52(11):1139-42. PubMed ID: 23196542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete genetic correction of ips cells from Duchenne muscular dystrophy.
    Kazuki Y; Hiratsuka M; Takiguchi M; Osaki M; Kajitani N; Hoshiya H; Hiramatsu K; Yoshino T; Kazuki K; Ishihara C; Takehara S; Higaki K; Nakagawa M; Takahashi K; Yamanaka S; Oshimura M
    Mol Ther; 2010 Feb; 18(2):386-93. PubMed ID: 19997091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy.
    Benedetti S; Uno N; Hoshiya H; Ragazzi M; Ferrari G; Kazuki Y; Moyle LA; Tonlorenzi R; Lombardo A; Chaouch S; Mouly V; Moore M; Popplewell L; Kazuki K; Katoh M; Naldini L; Dickson G; Messina G; Oshimura M; Cossu G; Tedesco FS
    EMBO Mol Med; 2018 Feb; 10(2):254-275. PubMed ID: 29242210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy.
    Tedesco FS; Hoshiya H; D'Antona G; Gerli MF; Messina G; Antonini S; Tonlorenzi R; Benedetti S; Berghella L; Torrente Y; Kazuki Y; Bottinelli R; Oshimura M; Cossu G
    Sci Transl Med; 2011 Aug; 3(96):96ra78. PubMed ID: 21849666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DYS-HAC-iPS cells: the combination of gene and cell therapy to treat duchenne muscular dystrophy.
    Park IH
    Mol Ther; 2010 Feb; 18(2):238-40. PubMed ID: 20125163
    [No Abstract]   [Full Text] [Related]  

  • 6. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
    Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
    Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells.
    Chaouch S; Mouly V; Goyenvalle A; Vulin A; Mamchaoui K; Negroni E; Di Santo J; Butler-Browne G; Torrente Y; Garcia L; Furling D
    Hum Gene Ther; 2009 Jul; 20(7):784-90. PubMed ID: 19358679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts.
    Loperfido M; Jarmin S; Dastidar S; Di Matteo M; Perini I; Moore M; Nair N; Samara-Kuko E; Athanasopoulos T; Tedesco FS; Dickson G; Sampaolesi M; VandenDriessche T; Chuah MK
    Nucleic Acids Res; 2016 Jan; 44(2):744-60. PubMed ID: 26682797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human artificial chromosomes for pluripotent stem cell-based tissue replacement therapy.
    Sinenko SA; Ponomartsev SV; Tomilin AN
    Exp Cell Res; 2020 Apr; 389(1):111882. PubMed ID: 32017931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion.
    Gonçalves MA; de Vries AA; Holkers M; van de Watering MJ; van der Velde I; van Nierop GP; Valerio D; Knaän-Shanzer S
    Hum Mol Genet; 2006 Jan; 15(2):213-21. PubMed ID: 16321987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy.
    Berry SE; Liu J; Chaney EJ; Kaufman SJ
    Regen Med; 2007 May; 2(3):275-88. PubMed ID: 17511564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene.
    Hoshiya H; Kazuki Y; Abe S; Takiguchi M; Kajitani N; Watanabe Y; Yoshino T; Shirayoshi Y; Higaki K; Messina G; Cossu G; Oshimura M
    Mol Ther; 2009 Feb; 17(2):309-17. PubMed ID: 19034264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toward gene and cell therapy using human artificial chromosome].
    Kazuki Y; Oshimura M
    Nihon Rinsho; 2011 Dec; 69(12):2142-7. PubMed ID: 22242311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Induced Pluripotent Stem Cells From Patients With Duchenne Muscular Dystrophy and Their Induction to Cardiomyocytes.
    Hashimoto A; Naito AT; Lee JK; Kitazume-Taneike R; Ito M; Yamaguchi T; Nakata R; Sumida T; Okada K; Nakagawa A; Higo T; Kuramoto Y; Sakai T; Tominaga K; Okinaga T; Kogaki S; Ozono K; Miyagawa S; Sawa Y; Sakata Y; Morita H; Umezawa A; Komuro I
    Int Heart J; 2016; 57(1):112-7. PubMed ID: 26673445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Induced pluripotent stem (iPS) cell-based cell therapy for muscular dystrophy: current progress and future prospects].
    Nishiyama T; Takeda S
    Brain Nerve; 2012 Jan; 64(1):39-46. PubMed ID: 22223500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic integration of the full-length dystrophin coding sequence in Duchenne muscular dystrophy induced pluripotent stem cells.
    Farruggio AP; Bhakta MS; du Bois H; Ma J; P Calos M
    Biotechnol J; 2017 Apr; 12(4):. PubMed ID: 28139886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.